A5065306642- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Bone health and treatments
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- Peptidase Inhibition and Analysis
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Gene expression and cancer classification
- Cancer Cells and Metastasis
- Chemotherapy-induced cardiotoxicity and mitigation
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Molecular Biology Techniques and Applications
- Nausea and vomiting management
Mayo Clinic in Florida
2016-2025
WinnMed
2016-2025
Jacksonville College
2016-2025
Dana-Farber Cancer Institute
2006-2024
Harvard University Press
2024
Oxford University Hospitals NHS Trust
2024
Federico Villarreal National University
2023
Atara Biotherapeutics (United States)
2023
University of Illinois Chicago
2021-2022
Alliance for Clinical Trials in Oncology
2015-2022
We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women surgically removed HER2-positive breast cancer.
Purpose To update the American Society of Clinical Oncology (ASCO)/College Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve accuracy HER2 and its utility as a predictive marker invasive cancer. Methods ASCO/CAP convened an Update Committee that included coauthors 2007 conduct systematic literature review optimal testing. Results The identified criteria areas requiring clarification by immunohistochemistry...
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.
Purpose: Using a 2 × factorial design, we studied the adjuvant chemotherapy of women with axillary node–positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) concurrent (AC) followed by (T) for disease-free (DFS) overall survival (OS); determine whether dose density agents improves DFS OS; toxicities. Patients Methods: A total 2,005 female patients were randomly assigned receive one following regimens: (I) 4 (doses) → T C doses every 3 weeks,...
To update the American Society of Clinical Oncology (ASCO)/College Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve accuracy HER2 and its utility as a predictive marker invasive cancer.
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, prospectively conducted study in uniformly treated population provides highest level evidence supporting clinical validity and usefulness biomarker.We performed prospective trial involving women hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary...
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs primary TNBCs two adjuvant phase III trials conducted by Eastern Cooperative Oncology Group (ECOG).Full-face hematoxylin eosin–stained sections 506 tumors from ECOG E2197 E1199 were evaluated for density intraepithelial (iTILs) stromal compartments (sTILs). Patient...
Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after years. The MA.17 trial, which was designed to determine whether extended therapy the aromatase inhibitor letrozole reduces risk such late recurrences, stopped early an interim analysis showed that improved disease-free survival. This report presents updated findings from trial.Postmenopausal completing treatment were randomly assigned a planned (n = 2593) or placebo 2594). primary endpoint...
Purpose This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those alone for first-line treatment patients human epidermal growth factor receptor 2–negative metastatic breast cancer. Patients Methods were randomly assigned in 2:1 ratio to plus BV or placebo. Before random assignment, investigators chose capecitabine (Cape; 2,000 mg/m 2 14 days), taxane (Tax) -based (nab-paclitaxel 260 , docetaxel 75 100 ),...
We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in adjuvant treatment breast cancer.
Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported 2005. One of these reports, the joint North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab Treating Women HER2-Overexpressing Breast Cancer) and National Surgical Adjuvant Bowel Project NSABP B-31 (Doxorubicin Cyclophosphamide...
Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of metabolites, but their effect on clinical outcome is unknown.We determined cytochrome P450 (CYP)2D6 (*4 and *6) CYP3A5 (*3) genotype from paraffin-embedded tumor samples buccal cells (living patients) tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial. The relationship between disease was using log-rank test Cox proportional hazards modeling.Paraffin blocks...
made in the treatment of early stage breast cancer.In patients with hormonesensitive tumors, tamoxifen reduces risk recurrence and death by more than 30%. 1 Moreover, aromatase inhibitors place or sequentially further postmenopausal women estrogenreceptor (ER)-positive tumors. [2]][4] In absence treatment, ER status is a weak prognostic factor, but it strong predictive factor sense that identifies who may benefit from endocrine therapy.With appropriate therapy, ER-positive disease have...
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Article Tools ASCO SPECIAL ARTICLE OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles CITATION DOI: 10.1200/JCO.1999.17.9.2971 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10561376 Recommendations for the Use Antiemetics: Evidence-Based, Practice Guidelines Richard J. GrallaxRichard GrallaSearch by this author , David OsobaxDavid OsobaSearch Mark G. KrisxMark KrisSearch Peter...
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has associated altered risk breast cancer and variable promoter activity. Therefore, we evaluated association VEGF genotype efficacy toxicity in E2100, a phase III study comparing paclitaxel versus plus bevacizumab as initial chemotherapy metastatic
To assess cardiac safety and potential risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial.
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy such patients scant. We tested for noninferiority capecitabine as compared standard who were 65 years age or older.We randomly assigned stage I, II, IIIA, IIIB to (either cyclophosphamide, methotrexate, fluorouracil cyclophosphamide plus doxorubicin) capecitabine. Endocrine therapy was recommended after hormone-receptor-positive tumors. A Bayesian statistical design used a...
BackgroundFor women with ductal carcinoma in situ (DCIS) of the breast, risk developing an ipsilateral breast event (IBE; defined as local recurrence DCIS or invasive carcinoma) after surgical excision without radiation is not well by clinical and pathologic characteristics.